Johnson & Johnson (JNJ) Long-Term Debt Repayments (2009 - 2024)

Johnson & Johnson's (JNJ) quarterly Long-Term Debt Repayments came in at $1.0 million in Q1 2024, down 99.8% year-on-year from $500.0 million in Q2 2023, and up 100.17% quarter-over-quarter from -$582.0 million in Q4 2023.

Johnson & Johnson (JNJ) Long-Term Debt Repayments (2009 - 2024) Analysis & Trends

Johnson & Johnson has disclosed Long-Term Debt Repayments across 16 years of filings, most recently posting $1.0 million for Q1 2024.

  • Long-Term Debt Repayments for Q1 2024 came in at $1.0 million, down 99.8% year-over-year; the trailing twelve-month figure through Mar 2024 was $601.0 million (down 78.65% YoY), and the FY2025 annual result was $1.8 billion, up 20.92% from the prior year.
  • Long-Term Debt Repayments came in at $1.0 million for Q1 2024 at Johnson & Johnson, up from -$582.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.1 billion in Q2 2022 to a low of -$582.0 million in Q4 2023.
  • The 5-year median for Long-Term Debt Repayments is $500.0 million (2023), against an average of $529.4 million.
  • Across the five-year window, Long-Term Debt Repayments jumped 18266.67% in 2020 and plunged 185.34% in 2023, its largest moves.
  • Johnson & Johnson's Long-Term Debt Repayments stood at $551.0 million in 2020, then plunged by 99.82% to $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then tumbled by 58300.0% to -$582.0 million in 2023, then surged by 100.17% to $1.0 million in 2024.
  • The last three Long-Term Debt Repayments figures came in at $1.0 million (Q1 2024), -$582.0 million (Q4 2023), and $500.0 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 750.00 Mn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 1.14 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 833.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 2.77 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 500.00 Mn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 1.00 Mn
Mar 31, 2024 1.00 Mn
Dec 31, 2023 -582.00 Mn
Dec 31, 2023 -582.00 Mn
Apr 2, 2023 500.00 Mn
Apr 2, 2023 500.00 Mn
Jan 1, 2023 682.00 Mn
Jan 1, 2023 682.00 Mn
Oct 2, 2022 1.00 Mn
Oct 2, 2022 1.00 Mn
Jul 3, 2022 1.63 Bn
Jul 3, 2022 1.63 Bn
Apr 3, 2022 2.13 Bn
Apr 3, 2022 2.13 Bn
Oct 3, 2021 1.00 Mn
Oct 3, 2021 1.00 Mn
Jul 4, 2021 450.00 Mn
Jul 4, 2021 450.00 Mn
Apr 4, 2021 1.00 Bn
Apr 4, 2021 1.00 Bn